Doses - MITOXANTRONE HCL
Dogs: 
As an alternative agent for the treatment of a variety of neoplastic diseases (see Indicationsabove): a) For lymphoproliferative disorders: 5 - 6 mg/m2 every 3 weeks (Gilson and Page 1994)
Cats: 
For soft-tissue sarcomas: a) 6 - 6.5 mg/2 IV given every 3 - 4 weeks for 4 - 6 treatments. (Keller and Helfand 1994)
Monitoring Parameters - 1) CBC with differential and platelets (see adverse effects section); 2)
Efficacy; 3) Chest radiographs, ECG or other cardiac function tests if cardiac symptomatologypresent; 4) Liver function tests if jaundice or other symptoms of hepatotoxicity present; 5) Serumuric acid levels for susceptible patients
Client Information - Clients should understand the potential costs and toxicities associated withtherapy. A blue-green color to urine or a bluish color to sclera may be noted but is of no concern.
Have clients report any symptoms associated with toxicity immediately to veterinarian.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None